HVTN 142: A Phase 1 Randomized Double-Blind Placebo-Controlled

Recruiting

99 years or below

All

1 Location

Brief description of study

The purpose of this study is to measure the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 10 May 2023. Study ID: 853495

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

HVTN 142: A Phase 1 Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Safety Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV

Brief description of study

Eligibility of study

Find a site

Interested in the study